BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | May 28, 2020
Product Development

Daily Chart: TIGIT pipeline heats up

With last week’s data from Genentech, the next-generation checkpoint target TIGIT has started to out-shine its peers. At least 11 TIGIT inhibitors are coming up behind Genentech’s tiragolumab in the pipeline. The Roche unit released...
BioCentury | May 27, 2020
Deals

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
BC Week In Review | Nov 17, 2017
Financial News

Immuno-oncology play Arcus raises $107M

On Nov. 13, immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling...
BC Extra | Nov 14, 2017
Financial News

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink...
BC Week In Review | Sep 22, 2017
Company News

Taiho gets option to Arcus' candidates

Cancer company Arcus Biosciences (Hayward, Calif.) granted Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) an option to develop and commercialize compounds in Japan and other Asian territories excluding China. Arcus said the deal includes anything listed...
BC Week In Review | Aug 18, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
BC Extra | Aug 17, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
Items per page:
1 - 8 of 8